Core Insights - electroCore, Inc. has announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to investigate the use of gammaCore™ Sapphire, a non-invasive vagus nerve stimulator (nVNS), as an adjunctive treatment for PTSD symptoms [1][2] Study Details - The study titled "Non-Invasive Vagus Nerve Stimulation (nVNS) for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder" will be led by Danielle DeSouza MSc, PhD, and aims to assess the safety and effectiveness of gammaCore Sapphire [2] - The primary safety measure will focus on significant adverse events (SAEs) related to nVNS treatment, while the primary efficacy outcome will be the change in the Clinician-Administered PTSD Scale (CAPS-5) total score after a 12-week treatment period [2] - The study will enroll up to 40 subjects aged 18 to 70 diagnosed with PTSD and is expected to last for 10 months [3] Background Information - Acacia Clinics is recognized for its expertise in precision neuromodulation and advanced mental health services, founded in 2018 by Dr. David Carreon and Dr. Nathan Meng [4] - electroCore, Inc. focuses on improving health through innovative non-invasive bioelectronic technologies, with products like gammaCore® and Quell® targeting chronic pain syndromes [5]

Core Insights - Silo Pharma, Inc. has received a Japanese patent for its lead asset SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD), which enhances its intellectual property portfolio [1][2] - The company is collaborating with Columbia University for the development of SPC-15, which is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders [2][3] - Silo Pharma's therapeutic focus includes addressing conditions such as PTSD, chronic pain, and central nervous system diseases, with a diverse portfolio of innovative programs [3] Patent and Intellectual Property - The Japan Patent Office granted patent number 7683882 to Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," which is exclusively licensed to Silo [1] - This patent adds to Silo's international intellectual property portfolio, reinforcing the protection for SPC-15 [2] Product Development - SPC-15 is positioned for potential eligibility under the FDA's streamlined 505(b)(2) regulatory pathway, which could expedite its approval process [2] - The company is conducting preclinical studies in collaboration with Columbia University and holds exclusive global rights for the development and commercialization of SPC-15 [2] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [3] - The company's portfolio includes other programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [3]